Jiangsu Vcare Secures Nearly CNY 200 Million in Series C+ Financing

New Progress in Autoimmune Disease Pipeline! Vcare PharmaTech's VC005 Topical Gel Secures China IND Approval for Plaque Psoriasis

Recently, VC005 topical gel, a new-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), has officially obtained the IND approval from the CDE for the topical treatment of plaque psoriasis.

View Details

Vcare PharmaTech Enters into Exclusive Licensing Agreement with Everest Medicines for Sumecigrel Across Multiple Asia-Pacific Countries and Regions

9 June 2026 – Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech，Company), a commercial-stage innovative biopharmaceutical firm leveraging AI for differentiated original drug design, today announced the signing of an exclusive licensing agreement with Everest Medicines (HKEX: 1952.HK). Under the deal, Vcare PharmaTech grants Everest Medicines exclusive rights for the clinical development, registration and commercialization of Sumecigrel (formerly known as Vicagrel) across multiple Asia-Pacific countries and regions (including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR and Taiwan region of China).

View Details

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

On June 4, the official website of the NMPA announced that Vcare PharmaTech’s Class 1 new drug, Eratrectinib (VELMARTO®), has been approved for marketing in China. It is indicated for adult and adolescent patients with advanced solid tumors harboring NTRK gene fusions.

View Details

Capital Empowers Innovation: Vcare PharmaTech Completes Nearly RMB 200 Million Series C3 Financing

Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) has successfully closed its Series C3 financing totaling nearly RMB 200 million. The round was led by existing shareholder Hongcheng Investment, with follow-on investments from institutions including Xinghe Venture Capital, Hangzhou Jinlong, Hongyao Kechuang and Huadian Investment. Meanwhile, the firm has onboarded high-caliber new investors such as Huafuruixing, consolidating a solid capital foundation for its sustainable long-term growth.

View Details

The Fourth Self-Developed Innovative Drug Enters Pivotal Clinical Stage! Jiangsu Vcare’s VC005 Topical Gel Completes First Patient Enrollment in Phase III Clinical Trial

Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Jiangsu Vcare) announced that VC005 Topical Gel, its self-developed second-generation highly selective JAK1 inhibitor, has completed the enrollment of the first patient in the phase III clinical trial for the treatment of mild-to-moderate atopic dermatitis (AD).

View Details

New Expansion in Topical Pipeline! Jiangsu Vcare’s VC005 Topical Gel Granted China IND Approval for New Indication of Vitiligo

Recently, VC005 Topical Gel, a second-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), has officially obtained the IND approval from the CDE of the NMPA. The product is intended for the topical treatment of non-segmental vitiligo.

View Details